Cargando…
BNT162b2 mRNA COVID-19 Vaccine: First Approval
BNT162b2 (Comirnaty(®); BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spik...
Autor principal: | Lamb, Yvette N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938284/ https://www.ncbi.nlm.nih.gov/pubmed/33683637 http://dx.doi.org/10.1007/s40265-021-01480-7 |
Ejemplares similares
-
Remdesivir: First Approval
por: Lamb, Yvette N.
Publicado: (2020) -
Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019) -
Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021) -
Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018) -
Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2021)